Labcorp (LH)
(Delayed Data from NYSE)
$222.22 USD
-2.37 (-1.06%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $222.22 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Price, Consensus and EPS Surprise
LH 222.22 -2.37(-1.06%)
Will LH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LH
Labcorp Stock Gains From Its Latest Acquisition of BioReference Health
Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes
LH: What are Zacks experts saying now?
Zacks Private Portfolio Services
LH Stock Expected to Gain From the Ballad Health Acquisition Deal
Should You Hold Labcorp (LH) Stock in Your Portfolio Now?
Labcorp (LH) Gains From New Collaborations Amid FX Issues
Other News for LH
Greenberg Traurig Advises OPKO Health in $237.5 Million Asset Sale to Labcorp
Labcorp price target raised by $4 at Baird, here's why
Ovia Health Expands Women's Health Offerings with Comprehensive Postpartum Experience
Labcorp subsidiary prices $2B notes offering
LABCORP PRICES $650,000,000 IN 4.350% SENIOR NOTES DUE 2030, $500,000,000 IN 4.550% SENIOR NOTES DUE 2032 AND $850,000,000 IN 4.800% SENIOR NOTES DUE 2034